Cargando…
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221343/ https://www.ncbi.nlm.nih.gov/pubmed/35740909 http://dx.doi.org/10.3390/biom12060784 |
_version_ | 1784732597992030208 |
---|---|
author | Rodríguez, Francisco Caruana, Pablo De la Fuente, Noa Español, Pía Gámez, María Balart, Josep Llurba, Elisa Rovira, Ramón Ruiz, Raúl Martín-Lorente, Cristina Corchero, José Luis Céspedes, María Virtudes |
author_facet | Rodríguez, Francisco Caruana, Pablo De la Fuente, Noa Español, Pía Gámez, María Balart, Josep Llurba, Elisa Rovira, Ramón Ruiz, Raúl Martín-Lorente, Cristina Corchero, José Luis Céspedes, María Virtudes |
author_sort | Rodríguez, Francisco |
collection | PubMed |
description | Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments. |
format | Online Article Text |
id | pubmed-9221343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92213432022-06-24 Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges Rodríguez, Francisco Caruana, Pablo De la Fuente, Noa Español, Pía Gámez, María Balart, Josep Llurba, Elisa Rovira, Ramón Ruiz, Raúl Martín-Lorente, Cristina Corchero, José Luis Céspedes, María Virtudes Biomolecules Review Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments. MDPI 2022-06-04 /pmc/articles/PMC9221343/ /pubmed/35740909 http://dx.doi.org/10.3390/biom12060784 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rodríguez, Francisco Caruana, Pablo De la Fuente, Noa Español, Pía Gámez, María Balart, Josep Llurba, Elisa Rovira, Ramón Ruiz, Raúl Martín-Lorente, Cristina Corchero, José Luis Céspedes, María Virtudes Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges |
title | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges |
title_full | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges |
title_fullStr | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges |
title_full_unstemmed | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges |
title_short | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges |
title_sort | nano-based approved pharmaceuticals for cancer treatment: present and future challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221343/ https://www.ncbi.nlm.nih.gov/pubmed/35740909 http://dx.doi.org/10.3390/biom12060784 |
work_keys_str_mv | AT rodriguezfrancisco nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT caruanapablo nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT delafuentenoa nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT espanolpia nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT gamezmaria nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT balartjosep nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT llurbaelisa nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT roviraramon nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT ruizraul nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT martinlorentecristina nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT corcherojoseluis nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges AT cespedesmariavirtudes nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges |